Literature DB >> 33318628

Gut microbiome, liver immunology, and liver diseases.

Rui Wang1, Ruqi Tang1, Bo Li1, Xiong Ma2, Bernd Schnabl3,4, Herbert Tilg5.   

Abstract

The gut microbiota is a complex and plastic consortium of microorganisms that are intricately connected with human physiology. The liver is a central immunological organ that is particularly enriched in innate immune cells and constantly exposed to circulating nutrients and endotoxins derived from the gut microbiota. The delicate interaction between the gut and liver prevents accidental immune activation against otherwise harmless antigens. Work on the interplay between the gut microbiota and liver has assisted in understanding the pathophysiology of various liver diseases. Of immense importance is the step from high-throughput sequencing (correlation) to mechanistic studies (causality) and therapeutic intervention. Here, we review the gut microbiota, liver immunology, and the interaction between the gut and liver. In addition, the impairment in the gut-liver axis found in various liver diseases is reviewed here, with an emphasis on alcohol-associated liver disease (ALD), nonalcoholic fatty liver disease (NAFLD), and autoimmune liver disease (AILD). On the basis of growing evidence from these preclinical studies, we propose that the gut-liver axis paves the way for targeted therapeutic modalities for liver diseases.

Entities:  

Keywords:  Alcohol liver disease; Autoimmune liver disease; Gut–liver axis; Microbiome; Nonalcoholic fatty liver disease

Mesh:

Year:  2020        PMID: 33318628      PMCID: PMC7852541          DOI: 10.1038/s41423-020-00592-6

Source DB:  PubMed          Journal:  Cell Mol Immunol        ISSN: 1672-7681            Impact factor:   11.530


  198 in total

1.  Diversity of the human intestinal microbial flora.

Authors:  Paul B Eckburg; Elisabeth M Bik; Charles N Bernstein; Elizabeth Purdom; Les Dethlefsen; Michael Sargent; Steven R Gill; Karen E Nelson; David A Relman
Journal:  Science       Date:  2005-04-14       Impact factor: 47.728

2.  Discordant temporal development of bacterial phyla and the emergence of core in the fecal microbiota of young children.

Authors:  Jing Cheng; Tamar Ringel-Kulka; Ineke Heikamp-de Jong; Yehuda Ringel; Ian Carroll; Willem M de Vos; Jarkko Salojärvi; Reetta Satokari
Journal:  ISME J       Date:  2015-10-02       Impact factor: 10.302

Review 3.  The changing epidemiology of liver diseases in the Asia-Pacific region.

Authors:  Martin C S Wong; Jason L W Huang; Jacob George; Junjie Huang; Colette Leung; Mohammed Eslam; Henry L Y Chan; Siew C Ng
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2019-01       Impact factor: 46.802

Review 4.  Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention.

Authors:  Zobair Younossi; Quentin M Anstee; Milena Marietti; Timothy Hardy; Linda Henry; Mohammed Eslam; Jacob George; Elisabetta Bugianesi
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2017-09-20       Impact factor: 46.802

Review 5.  Alcoholic liver disease.

Authors:  Helmut K Seitz; Ramon Bataller; Helena Cortez-Pinto; Bin Gao; Antoni Gual; Carolin Lackner; Philippe Mathurin; Sebastian Mueller; Gyongyi Szabo; Hidekazu Tsukamoto
Journal:  Nat Rev Dis Primers       Date:  2018-08-16       Impact factor: 52.329

Review 6.  Changes in the Epidemiology of Primary Biliary Cholangitis.

Authors:  Ana Lleo; Francesca Colapietro
Journal:  Clin Liver Dis       Date:  2018-08       Impact factor: 6.126

Review 7.  The gut-liver axis in liver disease: Pathophysiological basis for therapy.

Authors:  Agustín Albillos; Andrea de Gottardi; María Rescigno
Journal:  J Hepatol       Date:  2019-10-14       Impact factor: 25.083

Review 8.  The gut-liver axis and the intersection with the microbiome.

Authors:  Anupriya Tripathi; Justine Debelius; David A Brenner; Michael Karin; Rohit Loomba; Bernd Schnabl; Rob Knight
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2018-07       Impact factor: 46.802

9.  The Firmicutes/Bacteroidetes ratio of the human microbiota changes with age.

Authors:  D Mariat; O Firmesse; F Levenez; Vd Guimarăes; H Sokol; J Doré; G Corthier; J-P Furet
Journal:  BMC Microbiol       Date:  2009-06-09       Impact factor: 3.605

10.  Revised Estimates for the Number of Human and Bacteria Cells in the Body.

Authors:  Ron Sender; Shai Fuchs; Ron Milo
Journal:  PLoS Biol       Date:  2016-08-19       Impact factor: 8.029

View more
  32 in total

1.  Integrated omics analysis: the relationship between significantly increased Klebsiella post-hepatectomy and decreased hub-metabolite 3-methyl-2-oxobutanoic acid is associated with induced liver failure.

Authors:  Yu-Chong Peng; Xin-Hua Zhao; Chuan-Fa Zeng; Jing-Xuan Xu; Lu-Nan Qi; Le-Qun Li
Journal:  J Gastrointest Oncol       Date:  2022-02

Review 2.  HIV Pre-exposure Prophylaxis and Its Impact on the Gut Microbiome in Men Having Sex With Men.

Authors:  Nicola Luigi Bragazzi; Rola Khamisy-Farah; Christina Tsigalou; Naim Mahroum
Journal:  Front Microbiol       Date:  2022-06-23       Impact factor: 6.064

Review 3.  Intratumor microbiome in cancer progression: current developments, challenges and future trends.

Authors:  Jinyan Liu; Yi Zhang
Journal:  Biomark Res       Date:  2022-05-31

Review 4.  COVID-19 exit strategy during vaccine implementation: a balance between social distancing and herd immunity.

Authors:  Suhad Daher-Nashif; Rania Al-Anany; Menatalla Ali; Khadija Erradi; Elmoubasher Farag; Abdallah M Abdallah; Mohamed M Emara
Journal:  Arch Virol       Date:  2022-06-20       Impact factor: 2.685

Review 5.  Obesity I: Overview and molecular and biochemical mechanisms.

Authors:  Robert H Lustig; David Collier; Christopher Kassotis; Troy A Roepke; Min Ji Kim; Etienne Blanc; Robert Barouki; Amita Bansal; Matthew C Cave; Saurabh Chatterjee; Mahua Choudhury; Michael Gilbertson; Dominique Lagadic-Gossmann; Sarah Howard; Lars Lind; Craig R Tomlinson; Jan Vondracek; Jerrold J Heindel
Journal:  Biochem Pharmacol       Date:  2022-04-05       Impact factor: 6.100

Review 6.  Bile acids and their receptors: modulators and therapeutic targets in liver inflammation.

Authors:  Anna Bertolini; Romina Fiorotto; Mario Strazzabosco
Journal:  Semin Immunopathol       Date:  2022-04-12       Impact factor: 11.759

Review 7.  The Role of B Cells and B Cell Therapies in Immune-Mediated Liver Diseases.

Authors:  Tamsin Cargill; Emma L Culver
Journal:  Front Immunol       Date:  2021-04-14       Impact factor: 7.561

Review 8.  The Gut-Liver Axis in Chronic Liver Disease: A Macrophage Perspective.

Authors:  Kevin De Muynck; Bart Vanderborght; Hans Van Vlierberghe; Lindsey Devisscher
Journal:  Cells       Date:  2021-10-30       Impact factor: 6.600

Review 9.  The Gut-Liver Axis in Cholestatic Liver Diseases.

Authors:  Andreas Blesl; Vanessa Stadlbauer
Journal:  Nutrients       Date:  2021-03-21       Impact factor: 5.717

10.  Dual therapy with zinc acetate and rifaximin prevents from ethanol-induced liver fibrosis by maintaining intestinal barrier integrity.

Authors:  Yuki Fujimoto; Kosuke Kaji; Norihisa Nishimura; Masahide Enomoto; Koji Murata; Soichi Takeda; Hiroaki Takaya; Hideto Kawaratani; Kei Moriya; Tadashi Namisaki; Takemi Akahane; Hitoshi Yoshiji
Journal:  World J Gastroenterol       Date:  2021-12-28       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.